Sentences with phrase «major global disease»

It was founded in November 2005 to develop innovative vaccines against major global diseases.

Not exact matches

Important factors that could cause actual results to differ materially from those reflected in such forward - looking statements and that should be considered in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the timing, execution, and profitability of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost of accommodating, announced increases in the build rates of certain aircraft; 6) the effect on aircraft demand and build rates of changing customer preferences for business aircraft, including the effect of global economic conditions on the business aircraft market and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals as a result of global economic uncertainty or otherwise; 8) the effect of economic conditions in the industries and markets in which we operate in the U.S. and globally and any changes therein, including fluctuations in foreign currency exchange rates; 9) the success and timely execution of key milestones such as the receipt of necessary regulatory approvals, including our ability to obtain in a timely fashion any required regulatory or other third party approvals for the consummation of our announced acquisition of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price for our announced acquisition of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both in the U.S. and abroad; 20) the effect of changes in tax law, such as the effect of The Tax Cuts and Jobs Act (the «TCJA») that was enacted on December 22, 2017, and changes to the interpretations of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect of such changes; 21) any reduction in our credit ratings; 22) our dependence on our suppliers, as well as the cost and availability of raw materials and purchased components; 23) our ability to recruit and retain a critical mass of highly - skilled employees and our relationships with the unions representing many of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment of interest on, and principal of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness of any interest rate hedging programs; 28) the effectiveness of our internal control over financial reporting; 29) the outcome or impact of ongoing or future litigation, claims, and regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition of Asco in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and other business disruptions for ourselves and Asco as a result of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks of doing business internationally, including fluctuations in foreign current exchange rates, impositions of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.

It is the result of the Global Burden of Disease — Major Air Pollution Sources (GDB MAPS) project, an international collaboration of Tsinghua University, the Health Effects Institute, the Institute for Health Metrics and Evaluation (IHME), and the University of British Columbia.

How Traceability Can Help Prevent Foodborne Disease: A major impact stirring many in the packaging industry lately, Tejas Bhatt with the Institute of Food Technologists and the Global Food Traceability Institute, shared these considerations for traceability: food safety, food sustainability, food security and food defense (i.e. intentional contamination).

As well the WHO publication Global health risks: mortality and burden of disease attributable to selected major risks.

He has contributed opinions as an expert on vector - borne disease emergence for the European Food Safety Authority and the Global Strategic Alliances for the Coordination of Research on the Major Infectious Diseases of Animals and Zoonoses (STAR - IDAZ), is a member of the MACSUR European network on the impacts of climate change on food production via disease ecology, and is a Fellow of the Royal Entomological Society.

To compute how additional pollution from ships increases risk of disease for exposed populations, especially those living in coastal communities or along major shipping lanes and far inland in some nations like India, the team incorporated important underlying health information from the World Health Organization and Global Asthma Network.

An internationally - recognized scientist with more than 16 years of experience in translational immunoparasitology research and vaccine development for neglected tropical diseases, Bottazzi's major interest lies in the role of vaccines as control tools integrated into international public and global health programs and initiatives.

Cardiovascular disease (CVD) remains the major contributor to the global burden of disease worldwide.

Just one in 20 people worldwide (4 · 3 %) had no health problems in 2013, with a third of the world's population (2 · 3 billion individuals) experiencing more than five ailments, according to a major new analysis from the Global Burden of Disease Study (GBD) 2013, published in The Lancet.

Worm infections represent a major global public health problem, leading to a variety of debilitating diseases and conditions, such as anemia, elephantiasis, growth retardation and dysentery.

After Ebola, a new global body is needed to contain future major disease threats.

Influenza remains a major health problem in the United States, resulting each year in an estimated 36,000 deaths and 200,000 hospitalizations.4 Those who have been shown to be at high risk for the complications of influenza infection are children 6 to 23 months of age; healthy persons 65 years of age or older; adults and children with chronic diseases, including asthma, heart and lung disease, and diabetes; residents of nursing homes and other long - term care facilities; and pregnant women.4 It is for this reason that the Centers for Disease Control and Prevention (CDC) has recommended that these groups, together with health care workers and others with direct patient - care responsibilities, should be given priority for influenza vaccination this season in the face of the current shortage.1 Other high - priority groups include children and teenagers 6 months to 18 years of age whose underlying medical condition requires the daily use of aspirin and household members and out - of - home caregivers of infants less than 6 months old.1 Hence, in the case of vaccine shortages resulting either from the unanticipated loss of expected supplies or from the emergence of greater - than - expected global influenza activity — such as pandemic influenza, which would prompt a greater demand for vaccination5 — the capability of extending existing vaccine supplies by using alternative routes of vaccination that would require smaller doses could have important public health implicdisease, and diabetes; residents of nursing homes and other long - term care facilities; and pregnant women.4 It is for this reason that the Centers for Disease Control and Prevention (CDC) has recommended that these groups, together with health care workers and others with direct patient - care responsibilities, should be given priority for influenza vaccination this season in the face of the current shortage.1 Other high - priority groups include children and teenagers 6 months to 18 years of age whose underlying medical condition requires the daily use of aspirin and household members and out - of - home caregivers of infants less than 6 months old.1 Hence, in the case of vaccine shortages resulting either from the unanticipated loss of expected supplies or from the emergence of greater - than - expected global influenza activity — such as pandemic influenza, which would prompt a greater demand for vaccination5 — the capability of extending existing vaccine supplies by using alternative routes of vaccination that would require smaller doses could have important public health implicDisease Control and Prevention (CDC) has recommended that these groups, together with health care workers and others with direct patient - care responsibilities, should be given priority for influenza vaccination this season in the face of the current shortage.1 Other high - priority groups include children and teenagers 6 months to 18 years of age whose underlying medical condition requires the daily use of aspirin and household members and out - of - home caregivers of infants less than 6 months old.1 Hence, in the case of vaccine shortages resulting either from the unanticipated loss of expected supplies or from the emergence of greater - than - expected global influenza activity — such as pandemic influenza, which would prompt a greater demand for vaccination5 — the capability of extending existing vaccine supplies by using alternative routes of vaccination that would require smaller doses could have important public health implications.

She's currently in her third year at USC majoring in Health Promotion and Disease Prevention with a minor in Health Care Studies and in the Global Medicine masters program.

About Kessler Foundation: Kessler Foundation, a major nonprofit organization in the field of disability, is a global leader in rehabilitation research that seeks to improve cognition, mobility, and long - term outcomes - including employment - for people with neurological disabilities caused by diseases and injuries of the brain and spinal cord.

Kessler Foundation, a major nonprofit organization in the field of disability, is a global leader in rehabilitation research to improve cognition, mobility, and long - term outcomes - including employment - for people with neurological disabilities caused by diseases and injuries of the brain and spinal cord.

Malaria is a parasitic disease endemic to many parts of the developing world and is a major global health concern.

About Kessler Foundation Kessler Foundation, a major nonprofit organization in the field of disability, is a global leader in rehabilitation research that seeks to improve cognition, mobility and long - term outcomes, including employment, for people with neurological disabilities caused by diseases and injuries of the brain, spinal cord and muscles.

deCODE is a global leader in gene discovery — our population approach and resources have enabled us to isolate key genes contributing to major public health challenges from cardiovascular disease to cancer, genes that are providing us with drug targets rooted in the basic biology of disease.

A major public health issue, depression is estimated to become one of the top three contributors to the global burden of diseases within a few years.

These diseases are quickly becoming a major global health problem.

DENVER / Oct 14, 2015 — Morris Animal Foundation, a global leader in supporting scientific research that advances the health and well - being of animals worldwide, has announced a major initiative to find a cure, treatments and / or vaccine for a disease that kills thousands of cats every year — feline infectious peritonitis.

Comparative Quantification of Health Risks: Global and Regional Burden of Disease due to Selected Major Risk Factors.

Other aspects of global warming's broad footprint on the world's ecosystems include changes in the abundance of more than 80 percent of the thousands of species included in population studies; major poleward shifts in living ranges as warm regions become hot, and cold regions become warmer; major increases (in the south) and decreases (in the north) of the abundance of plankton, which forms the critical base of the ocean's food chain; the transformation of previously innocuous insect species like the Aspen leaf miner into pests that have damaged millions of acres of forest; and an increase in the range and abundance of human pathogens like the cholera - causing bacteria Vibrio, the mosquito - borne dengue virus, and the ticks that carry Lyme disease - causing bacteria.

«There is no solid scientific evidence to date that global warming has been a major driving force of the twentieth century increase in epidemic infectious diseases,» he said.

«The environmental changes wrought by global warming will undoubtedly result in major ecologic changes that will alter patterns and intensity of some infectious diseases,» said Gerald Friedland, professor of medicine and epidemiology and public health at the Yale School of Medicine.

A report from WHO showed that respiratory and cardiovascular diseases, categorised as lifestyle ailments, are a major threat across the globe — accounting for 38 million global deaths, annually.